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NONSYNDROMIC PARKINSON DISEASE IN
A FAMILY WITH AUTOSOMAL DOMINANT OPTIC
ATROPHY DUE TO OPA1 MUTATIONS
Many genes implicated in familial Parkinson disease
(PD) code for proteins with mitochondrial function.1
Several of these genes, including PINK1 and PARK2,
are involved in mitophagy, a mitochondrial quality
control pathway.2 We describe a family with 3 mem-
bers affected by autosomal dominant optic atrophy in
which 2 affected members also developed PD.
While the role of mitophagy-related genes in PD is
well established, this report provides further evidence
of PD risk conferred through abnormal mitochon-
drial fusion and cristae morphology.
Clinical description. Patient 1 (P1) developed
visual impairment in childhood. She was severely
affected by optic atrophy but otherwise well until
age 70 years. She then developed depression, fol-
lowed by asymmetric upper limb tremor. This
was accompanied by postural instability and a bra-
dykinetic gait. She was diagnosed with PD and has
a moderate response to levodopa. Patient 2 (P2)
developed visual symptoms at age 9 years and was
diagnosed with optic atrophy. Her vision deterio-
rated in her 20s, but she remained well until age
40 years when she developed gait difficulty and
upper limb rest tremor. She was diagnosed with
PD and has a moderate response to both levodopa
and dopamine agonists. During examination at age
53 years, she had Hoehn and Yahr Stage 2 PD.
Additional features, such as dementia, neuropathy,
or deafness, were not present in P1 or P2. The
youngest sibling, patient 3 (P3), was diagnosed
with optic atrophy at age 14 years, and while visu-
ally impaired, remained mildly affected and can
drive and read without magnification at age 40
years. She does not fulfill clinical diagnostic criteria
for PD at this time. See figure, A for pedigree.
Both P2 and P3 were clinically assessed using
a test battery used in the PREDICT-PD study,
a population-based cohort in which participants
are risk stratified for future PD using a variety of
determinants.3 P2, who already carried a diagnosis
of PD, scored 16/40 in the University of Pennsyl-
vania Smell Identification Test (UPSIT),
indicating anosmia. Her sister, P3, scored 33/40
in the UPSIT, which is within the normal range.
A validated assessment of bradykinesia and incoor-
dination, the BRAIN test, was performed by both
P2 and P3. P2 scored in the low normal range for
speed with a prolonged dwell time. She was also
inaccurate and had poor rhythm. P3 scored in the
normal range for speed, accuracy, and dwell time.
These findings support the clinical observation that
P3 does not fulfill motor criteria for PD, nor does
she have objective olfactory or motor dysfunction
that might suggest prodromal disease. She is, how-
ever, 10 years younger than her affected sister.
All 3 patients were found to carry the same hetero-
zygous deletion of exons 28 and 29 of OPA1. We
excluded point mutations in autosomal dominant
PD genes via focused exome sequencing in patient
P2 (Illumina TruSight One). Specifically, no rare
variants were detected in SNCA, LRRK2, GBA,
PINK1, PARK2, or HTRA2. An unrelated patient
(OC) carrying a heterozygous frameshift mutation
at the beginning of exon 28 (c.2708_2711 delTTAG)
was used as a control. He was not affected with and
had no family history of PD.
Methods. All 5 members of the family and patient
OC underwent skin biopsy and dermal fibroblast
culture. OPA1 protein levels were determined by
Western blotting from whole cell lysates using the
anti-OPA1 antibody (BD Biosciences), which rec-
ognizes both long and short isoforms of OPA1.
Anti-b-actin was used as a loading control (Abcam,
Cambridge, United Kingdom). Transmission
electron microscopy (TEM) was used to investigate
mitochondrial cristae morphology. Cells were
fixed and imaged, and mitochondrial morphology
was scored in a masked way in which a score of
3 indicated normal cristae morphology, a score
of 2 indicated internal disorganization, and a score
of 1 indicated mitochondria with severely damaged
cristae.4,5 Mitochondrial networks were assessed in
live cells after staining the mitochondria with tet-
ramethylrhodamine and imaging at 403 under
an Opera Phenix Microscope (Perkin Elmer,
Waltham, MA).
Results. All affected patients showed an approxi-
mate 50% reduction in OPA1 levels by Western
Neurology.org/ng Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology 1
blotting (figure, B), in keeping with haploinsuffi-
ciency. Examination of mitochondrial morphology
by TEM revealed a significant increase in abnormal
cristae in P1, P2, and P3, compared with their
unaffected family members (figure, C). This phe-
notype was not shared by the unaffected OPA1
patient OC, despite all affected patients showing
similar disruption of the mitochondrial network
in live cell imaging (figure, D).
Discussion. Mutations in a number of nuclear-
encoded mitochondrial genes are known to cause
PD, some of which lead to dysfunction of mito-
chondrial quality control (mitophagy). In 1 pre-
vious report, a form of syndromic PD with
dementia, neuropathy, and deafness was associated
with OPA1 mutations.6 Dysregulated mitophagy
and mitochondrial networks have also been de-
tected in OPA1 patient cells.7 This report further
implicates OPA1 in nonsyndromic, idiopathic PD
associated with abnormal cristae morphology and
mitochondrial networks.
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Figure Pedigree, immunoblot mitochondrial morphology score, and confocal microscopy images of mitochondrial networks showing
representative cells
(A) Pedigree, in which filled boxes represent OPA1 mutation carriers. (B) Immunoblot demonstrating reduced OPA1 protein levels in all affected
patients. (C) Mitochondrial morphology score demonstrating a significant increase in the number of abnormal mitochondrial cristae found in patients
P1, P2, and P3. Examples of each score are shown using white arrows. (D) Confocal microscopy images of mitochondrial networks showing repre-
sentative cells. OPA1 patient cells showed an increased number of fragmented mitochondrial networks compared with controls. PD 5 Parkinson
disease.
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